据了解，绿叶制药此前通过收购博安生物98%股权将其纳入体系，获取其抗体药管线、技术平台与生产 资产，后续通过山东绿叶制药有限公司持股，成为其核心控股主体。截至2025年，山东绿叶制药有限公 司持有博安生物70.81%股份。博安生物是绿叶制药从传统小分子向生物药升级的关键载体，助力其构 建 "化学药 + 生物药" 双线研发体系。 智通财经APP获悉，博安生物(06955)涨近5%，截至发稿，涨4.23%，报9.12港元，成交额3.58亿港元。 消息面上，1月21日，博安生物发布公告，董事会已获控股股东绿叶制药集团知会，根据与可交换优先 股相关的认购协议的条款，拟安排绿叶制药的全资附属公司山东绿叶制药有限公司于2026年1月22日向 发行人Luye Geneora Holding Limited进一步于市场转让3850万股H股，作为拟议转让的一部分。 ...

Group 1 - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharma Group, regarding a subscription agreement related to exchangeable preferred shares [1] - Luye Pharma's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., is set to transfer 38.5 million H-shares to the issuer, Luye Geneora Holding Limited, on January 22, 2026, as part of the proposed transfer [1]

Core Viewpoint - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharmaceutical Group, regarding a proposed transfer of 38.5 million H-shares by its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to the issuer Luye Geneora Holding Limited on January 22, 2026 [1] Group 1 - The controlling shareholder, Luye Pharmaceutical Group, is involved in a share transfer agreement related to exchangeable preferred shares [1] - The proposed transfer involves a significant number of shares, specifically 38.5 million H-shares [1] - The transaction is scheduled to take place on January 22, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 自願性公告 控股股東轉讓股份 本公告由 山東博安生物技術 股份有限公司（「本公司」）自 願 刊 發。 茲提述本公司日期為2026年1月11日之公告（「該公告」），內 容 有 關（其 中 包 括）本 公司控股股東 綠葉製藥集團有限公司（「綠葉製藥」，連 同 其 附 屬 公 司 統 稱「綠 葉 製藥集團」）擬轉讓本公司股本中之H股（「擬議轉讓」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 本公司董事會（「董事會」）已 獲 綠 葉 製 藥 集 團 知 會，根 據 與 ...

Core Viewpoint - The company, Luye Pharma Group, has announced an increase in trading volume of its H-shares and confirmed that it is unaware of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares [1][2]. Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which allow holders to exchange these shares for existing H-shares held by Luye Pharma Group [1][2]. - Following the issuance of the exchangeable preferred shares, an agreement was made to transfer 100.5 million H-shares to a designated custody account to fulfill the exchange rights associated with these shares [2]. - On January 9, 2026, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer in the market [2]. Group 2: Product Development and Approval - The company's self-developed drug, BA6101 (60mg), has been approved for market launch by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2][3]. - BA6101 is a biosimilar to the reference drug Prolia®, widely used for the treatment of osteoporosis, and has the same indications as the reference drug [3]. - The development of BA6101 adheres to international guidelines and has demonstrated high similarity in quality, safety, and efficacy compared to the reference drug, with no clinically significant differences [3]. Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and enhance the accessibility of the drug for patients, providing more treatment options [4]. - Strategic partnerships have been established for the commercialization of BA6101 in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [4]. - The company aims to accelerate its international strategy by offering high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [4].

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]

Major Events - GCL-Poly Energy (00451) plans to issue 186.5 million subscription shares to partner with Pharos to accelerate the integration of Web3 and the renewable energy industry [1] - Hansoh Pharmaceutical (03692) receives drug registration certificate from the National Medical Products Administration for the fifth indication of Amelot (Ametinib Mesylate Tablets) [1] - Green Leaf Pharmaceutical (02186) has its application for the new indication of the innovative drug Ruoxinlin for the treatment of generalized anxiety disorder accepted in China [1] - Xianjian Technology (01302) receives formal registration approval from the National Medical Products Administration for the G-iliacTM Pro iliac artery covered stent system [1] - Meirui Health International (02327) plans to acquire 100% equity of Jiangsu Yide for 125 million yuan [1] - Century International (00959) joint venture signs a memorandum of understanding with WPT to jointly develop, operate, and commercialize mobile applications [1] Operating Performance - Fast Retailing (06288) reports first-quarter earnings with a net profit attributable to shareholders of 147.445 billion yen, an increase of 11.7% year-on-year [1] - Agile Group (01813) reports December pre-sale amount of 420 million yuan, a decrease of 56.7% year-on-year [1] - Baolong Real Estate (01238) projects total contract sales of approximately 7.272 billion yuan for 2025, a decrease of 43.13% year-on-year [1] - China General Nuclear Power (01816) expects total on-grid electricity of approximately 2,326.48 billion kilowatt-hours for 2025, an increase of 2.36% year-on-year [1] - Lingbao Gold (03330) issues a profit warning, expecting net profit for the 2025 fiscal year to be approximately 1.503 to 1.573 billion yuan, an increase of about 115% to 125% year-on-year [1]

Core Viewpoint - Green Leaf Pharmaceutical has received formal acceptance from the National Medical Products Administration for the new indication application of its innovative drug Ruoxinlin, aimed at treating generalized anxiety disorder, marking a significant milestone since its approval for depression treatment in November 2022 [1] Group 1: Drug Development and Clinical Research - Ruoxinlin is expected to be the first SNDRI (serotonin, norepinephrine, and dopamine reuptake inhibitor) for generalized anxiety disorder in China, potentially benefiting a larger patient population [1] - The new indication application is based on a Phase III clinical study involving 555 patients, demonstrating an efficacy rate exceeding 80% and a remission rate of approximately 50% [1] - The safety profile of Ruoxinlin is favorable, with low incidences of adverse effects such as drowsiness, insomnia, fatigue, and sexual dysfunction, most of which are mild to moderate and tend to improve over time [1] Group 2: Market Context and Demand - Anxiety disorders are the most common mental disorders in China, with approximately 58.67 million affected individuals, and generalized anxiety disorder has a lifetime prevalence of about 4.1%-6.6% among adults [2] - Current first-line treatments for generalized anxiety disorder, SSRIs and SNRIs, show limited efficacy with overall effectiveness rates of 67.7% and remission rates of only 39.7%, alongside significant side effects that affect patient compliance [2] - The market for SSRIs and SNRIs is projected to reach 4.83 billion yuan in 2024, with no new innovative drugs approved in the last 20 years, highlighting a significant gap in the treatment landscape [2] Group 3: Company Strategy and Product Portfolio - Green Leaf Pharmaceutical has established a long-term strategic focus on the central nervous system treatment field, with a diverse product portfolio addressing various conditions including schizophrenia, bipolar disorder, and Alzheimer's disease [4] - The company’s product lineup includes Ruoxinlin, which has served nearly 190,000 patients since its launch, and has been recognized as one of the fastest-growing antidepressants in China [3] - The company is actively developing next-generation innovative drugs, with several candidates in clinical stages targeting multiple mechanisms [4]

Core Viewpoint - Green Leaf Pharmaceutical has received formal acceptance from the National Medical Products Administration for the new indication application of its innovative drug Ruoxinlin® for the treatment of generalized anxiety disorder, marking a significant milestone since its approval for depression treatment in November 2022 [1] Group 1: Product Development and Clinical Research - Ruoxinlin® is expected to be the first SNDRI in China for treating generalized anxiety disorder, potentially benefiting a larger patient population [1] - The new indication application is based on a Phase III clinical study involving 555 patients, demonstrating an efficacy rate exceeding 80% and a remission rate of approximately 50% [1] - The safety profile of Ruoxinlin® is favorable, with low incidences of adverse reactions such as drowsiness and sexual dysfunction, and no significant impact on weight or glucose-lipid metabolism [1] Group 2: Market Context and Demand - Anxiety disorders are the most common mental disorders in China, with approximately 58.67 million affected individuals, and the lifetime prevalence of generalized anxiety disorder in adults is estimated at 4.1%-6.6% [2] - Current first-line treatments, SSRIs and SNRIs, have limited efficacy, with overall effectiveness rates of 67.7% and remission rates of only 39.7%, alongside common adverse effects that affect patient compliance [2] - The market for SSRIs and SNRIs is projected to reach 4.83 billion yuan in 2024, with no new innovative drugs approved in the last 20 years, highlighting a significant gap in the treatment landscape [2] Group 3: Company Strategy and Product Portfolio - The central nervous system treatment area, including depression and anxiety, is a core strategic focus for the company, which has developed a differentiated product portfolio addressing various mental health conditions [4] - In addition to Ruoxinlin®, the company’s portfolio includes other approved products such as Erzofri® and Rykindo®, and it is actively developing next-generation innovative drugs targeting multiple mechanisms [4] - Ruoxinlin® has served nearly 190,000 patients since its launch, gaining recognition for its efficacy and safety, and is expected to further enhance accessibility with its new indication [3]